31806
document
Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin : results from a randomized , placebo-controlled , double-blind trial . AIM The aim of this study was to investigate whether amantadine reduces deterioration of quality of life in patients with chronic hepatitis C during and after treatment with interferon-alpha ( IFN-alpha ) and ribavirin . PATIENTS AND METHODS In this randomized , prospective , placebo-controlled , multicenter trial , previously untreated patients with chronic hepatitis C were treated with IFN-alpha plus ribavirin [ 17 ] and randomized for treatment with amantadine ( 200 mg/day , orally , n=136 ) or placebo ( n=131 ) . Quality of life was assessed with the 'Profile of Mood States ' scale and the 'Everyday Life ' questionnaire at baseline , treatment week ( TW ) 8 , TW24 , TW48 , and at follow-up . RESULTS Early during treatment at TW8 , quality of life was not different between patients in the control and the amantadine group . At TW24 , the control group but not the amantadine group , however , showed significant deterioration of the modalities depression , fatigue , and vigor compared with baseline . Especially , nonresponders in the amantadine group showed significantly lower deterioration of depression , anger , mind function , everyday life , and zest for life than those in the placebo group . After treatment , the beneficial effects of amantadine disappeared . CONCLUSION The addition of amantadine to IFN-alpha plus ribavirin combination therapy may reduce deterioration of depression , fatigue , and vigor during treatment but does not affect quality of life after treatment .
31807
Intervention_Pharmacological
amantadine
31808
Intervention_Pharmacological
interferon-alpha and ribavirin
31809
Intervention_Control
placebo-controlled
31810
Intervention_Control
placebo-controlled
31811
Intervention_Pharmacological
IFN-alpha plus ribavirin [ 17 ]
31812
Intervention_Pharmacological
amantadine
31813
Intervention_Control
placebo
31814
Intervention_Pharmacological
amantadine
31815
Intervention_Control
placebo
31816
Intervention_Pharmacological
amantadine
31817
Intervention_Pharmacological
IFN-alpha plus ribavirin
31818
Outcome_Other
Efficacy
31819
Outcome_Other
quality of life
31820
Outcome_Other
deterioration of quality of life
31821
Outcome_Other
Quality of life
31822
Outcome_Mental
'Profile of Mood States ' scale
31823
Outcome_Other
and the 'Everyday Life ' questionnaire
31824
Outcome_Physical
modalities depression
31825
Outcome_Physical
fatigue , and vigor
31826
Outcome_Physical
lower deterioration of depression
31827
Outcome_Physical
anger
31828
Outcome_Mental
,
31829
Outcome_Physical
mind function
31830
Outcome_Mental
, everyday life , and zest for life
31831
Outcome_Other
beneficial effects
31832
Outcome_Physical
deterioration of depression
31833
Outcome_Physical
fatigue
31834
Outcome_Physical
vigor
31835
Outcome_Other
quality of life
31836
Participant_Condition
chronic hepatitis C
31837
Participant_Condition
chronic hepatitis C
31838
Participant_Condition
previously untreated patients
31839
Participant_Condition
chronic hepatitis C